• Skip to main content
  • Skip to navigation
Home

YEDA Technology Transfer from the Weizmann Institute of Science

Yeda Research and Development

Briefcase
Become a member
Menu
  • Home
  • About Us
    • About Us
    • Our Team
    • Board of Directors
    • Close
  • Technologies
    • Agriculture and Plant Genetics
    • Chemistry and Nanotechnology
    • Diagnostics
    • Environmental Sciences and Solar Energy
    • Mathematics and Computer Science
    • Medical Devices
    • Pharmaceuticals
    • Physics and Electro-Optics
    • Research Tools
    • Close
  • Success Stories
    • Products
    • Companies
    • Close
  • News & events
  • For researchers
  • Contact
  • Become a Member
  • Close
  • Technologies(140)
  • Research Experts(88)
  • Success Stories(47)
  • News & Events(57)

You are here

  1. Home ›
  2. Search ›
  3. Technologies

Results for technologies (3)

Advanced filter
Pharmaceuticals

Treatment for Ewing Sarcoma Using ETS Proteins (No. T4-2068)

Ewing sarcoma (ES) is a common bone malignancy in children and young adolescents which is usually treated by systemic chemotherapy. In about 25% of the cases, cancer has already spread to other parts of the body at the time of diagnosis. Ewing sarcoma is the second most common ped... Read more
Extension Service Yosef Yarden

Yosef Yarden

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
6154
Pharmaceuticals

Treatment for Drug-Resistant Non-Small Cell Lung Cancer (No. T4-1944)

Non-Small Cell Lung Cancer (NSCLC) is a very common type of cancer, and despite currently available therapies, is one of the deadliest due to the emergence of drug resistance, which results in tumor recurrence. Lung cancer is one of the most deadly and common types of cancer in th... Read more
Extension Service Yosef Yarden

Yosef Yarden

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
6025
Pharmaceuticals

Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (No. T4-1774)

A novel method to treat tyrosine kinase inhibitor (TKI) resistant cancer by using a combination of three antibodies that target EGFR (ERBB1), HER2 (ERBB2), and HER3 (ERBB3) receptors. The ErbB/HER family of receptor tyrosine kinases includes epidermal growth factor receptor (EGFR... Read more
Extension Service Yosef Yarden

Yosef Yarden

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
5635

User login

  • Home
  • About Us
    • About Us
    • Our Team
    • Board of Directors
    • Close
  • Technologies
    • Agriculture and Plant Genetics
    • Chemistry and Nanotechnology
    • Diagnostics
    • Environmental Sciences and Solar Energy
    • Mathematics and Computer Science
    • Medical Devices
    • Pharmaceuticals
    • Physics and Electro-Optics
    • Research Tools
    • Close
  • Success Stories
    • Products
    • Companies
    • Close
  • News & events
  • For researchers
  • Contact
  • Become a Member
  • Close

footer

Yeda Research & Development Co. Ltd, P.O Box 95, Rehovot 7610002, Israel
Tel. +972.8.9470617 | Fax. +972.8.9470739
Privacy-Policy youtube twitter facebook linkedin instagram